162 related articles for article (PubMed ID: 23033898)
1. p63 as a prognostic marker for giant cell tumor of bone.
Yanagisawa M; Kakizaki H; Okada K; Torigoe T; Kusumi T
Ups J Med Sci; 2013 Mar; 118(1):23-8. PubMed ID: 23033898
[TBL] [Abstract][Full Text] [Related]
2. A clinicopathological study of giant cell tumor of small bones.
Yanagisawa M; Okada K; Tajino T; Torigoe T; Kawai A; Nishida J
Ups J Med Sci; 2011 Nov; 116(4):265-8. PubMed ID: 21919814
[TBL] [Abstract][Full Text] [Related]
3. P63 expression as a biomarker discriminating giant cell tumor of bone from other giant cell-rich bone lesions.
Shooshtarizadeh T; Rahimi M; Movahedinia S
Pathol Res Pract; 2016 Oct; 212(10):876-879. PubMed ID: 27473669
[TBL] [Abstract][Full Text] [Related]
4. Utility of P63 in Differentiating Giant Cell Tumor from Other Giant Cell-Containing Lesions.
Hui M; Uppin SG; Kumar KK; Radhika S; Chandrasekhar P; Rao KN
Turk Patoloji Derg; 2022; 38(1):9-15. PubMed ID: 34514571
[TBL] [Abstract][Full Text] [Related]
5. Can p63 serve as a biomarker for giant cell tumor of bone? A Moroccan experience.
Hammas N; Laila C; Youssef AL; Hind el F; Harmouch T; Siham T; Afaf A
Diagn Pathol; 2012 Sep; 7():130. PubMed ID: 23016917
[TBL] [Abstract][Full Text] [Related]
6. [Factors related to biologic behavior in giant cell tumor of bone].
Ran XY; Huang J; Zhang HZ; Jiang ZM; Chen J
Zhonghua Bing Li Xue Za Zhi; 2013 Oct; 42(10):669-74. PubMed ID: 24433729
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemistry for histone H3G34W and H3K36M is highly specific for giant cell tumor of bone and chondroblastoma, respectively, in FNA and core needle biopsy.
Schaefer IM; Fletcher JA; Nielsen GP; Shih AR; Ferrone ML; Hornick JL; Qian X
Cancer Cytopathol; 2018 Aug; 126(8):552-566. PubMed ID: 29757500
[TBL] [Abstract][Full Text] [Related]
8. A Comparative Analysis of p63 Expression in Giant Cell Tumour (GCT), Central Giant Cell Granuloma (CGCG) and Peripheral Giant Cell Granuloma (PGCG).
Nagar SR; Bansal S; Jashnani K; Sinha A; Desai RS
Head Neck Pathol; 2020 Sep; 14(3):733-741. PubMed ID: 31873936
[TBL] [Abstract][Full Text] [Related]
9. A diagnosis of giant cell-rich tumour of bone is supported by p63 immunohistochemistry, when more than 50 % of cells is stained.
Maues De Paula A; Vasiljevic A; Giorgi R; Gomez-Brouchet A; Aubert S; Leroy X; Duval H; de Pinieux G; Bouvier C
Virchows Arch; 2014 Oct; 465(4):487-94. PubMed ID: 25100342
[TBL] [Abstract][Full Text] [Related]
10. Histopathology of giant cell tumors of the bone: With special emphasis on fibrohistiocytic and aneurysmal bone cyst like components.
Çomunoğlu N; Kepil N; Dervişoğlu S
Acta Orthop Traumatol Turc; 2019 Jan; 53(1):35-39. PubMed ID: 30392920
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation profile discriminates sporadic giant cell granulomas of the jaws and cherubism from their giant cell-rich histological mimics.
Guimarães LM; Baumhoer D; Andrei V; Friedel D; Koelsche C; Gomez RS; von Deimling A; Gomes CC
J Pathol Clin Res; 2023 Nov; 9(6):464-474. PubMed ID: 37555357
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling identifies p63 as a diagnostic marker for giant cell tumor of the bone.
Lee CH; Espinosa I; Jensen KC; Subramanian S; Zhu SX; Varma S; Montgomery KD; Nielsen TO; van de Rijn M; West RB
Mod Pathol; 2008 May; 21(5):531-9. PubMed ID: 18192965
[TBL] [Abstract][Full Text] [Related]
13. Expression of VEGF and MMP-9 in giant cell tumor of bone and other osteolytic lesions.
Kumta SM; Huang L; Cheng YY; Chow LT; Lee KM; Zheng MH
Life Sci; 2003 Aug; 73(11):1427-36. PubMed ID: 12850503
[TBL] [Abstract][Full Text] [Related]
14. The prognostic factors of recurrent GCT: a cooperative study by the Eastern Asian Musculoskeletal Oncology Group.
Takeuchi A; Tsuchiya H; Niu X; Ueda T; Jeon DG; Wang EH; Asavamongkolkul A; Kusuzaki K; Sakayama K; Kang YK
J Orthop Sci; 2011 Mar; 16(2):196-202. PubMed ID: 21301899
[TBL] [Abstract][Full Text] [Related]
15. Histologic Spectrum of Giant Cell Tumor (GCT) of Bone in Patients 18 Years of Age and Below: A Study of 63 Patients.
Al-Ibraheemi A; Inwards CY; Zreik RT; Wenger DE; Jenkins SM; Carter JM; Boland JM; Rose PS; Jin L; Oliveira AM; Fritchie KJ
Am J Surg Pathol; 2016 Dec; 40(12):1702-1712. PubMed ID: 27526293
[TBL] [Abstract][Full Text] [Related]
16. Does Denosumab Change the Giant Cell Tumor Treatment Strategy? Lessons Learned From Early Experience.
Agarwal MG; Gundavda MK; Gupta R; Reddy R
Clin Orthop Relat Res; 2018 Sep; 476(9):1773-1782. PubMed ID: 30794215
[TBL] [Abstract][Full Text] [Related]
17. Higher local recurrence rates after intralesional surgery for giant cell tumor of the proximal femur compared to other sites.
Errani C; Tsukamoto S; Leone G; Akahane M; Cevolani L; Tanzi P; Kido A; Honoki K; Tanaka Y; Donati DM
Eur J Orthop Surg Traumatol; 2017 Aug; 27(6):813-819. PubMed ID: 28589498
[TBL] [Abstract][Full Text] [Related]
18. Segmental excision versus intralesional curettage with adjuvant therapy for giant cell tumour of bone.
Yacob O; Umer M; Gul M; Qadir I
J Orthop Surg (Hong Kong); 2016 Apr; 24(1):88-91. PubMed ID: 27122520
[TBL] [Abstract][Full Text] [Related]
19. Giant cell tumor of bone express p63.
Dickson BC; Li SQ; Wunder JS; Ferguson PC; Eslami B; Werier JA; Turcotte RE; Kandel RA
Mod Pathol; 2008 Apr; 21(4):369-75. PubMed ID: 18311114
[TBL] [Abstract][Full Text] [Related]
20. Retrospective analysis of 51 intralesionally treated cases with progressed giant cell tumor of the bone: local adjuvant use of hydrogen peroxide reduces the risk for tumor recurrence.
Omlor GW; Lange J; Streit M; Gantz S; Merle C; Germann T; Mechtersheimer G; Fellenberg J; Lehner B
World J Surg Oncol; 2019 Apr; 17(1):73. PubMed ID: 31014317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
